Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1922 1
1985 1
1987 1
1990 1
1991 3
1992 2
1993 2
1994 1
1995 1
1996 2
1997 1
1998 4
2004 1
2006 2
2007 2
2008 4
2009 8
2010 4
2011 5
2012 8
2013 9
2014 2
2015 11
2016 11
2017 9
2018 7
2019 9
2020 10
2021 11
2022 8
2023 8
2024 9
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.
Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Devlin N, Dorme L, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium. Coens C, et al. Among authors: pe m. Lancet Oncol. 2020 Feb;21(2):e83-e96. doi: 10.1016/S1470-2045(19)30790-9. Lancet Oncol. 2020. PMID: 32007209 Free article. Review.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM. Bührer E, et al. Among authors: pe m. Lancet Oncol. 2024 Sep;25(9):1202-1212. doi: 10.1016/S1470-2045(24)00338-3. Epub 2024 Aug 12. Lancet Oncol. 2024. PMID: 39146951 Clinical Trial.
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.
Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A; SISAQOL-IMI Consortium. Pe M, et al. Lancet Oncol. 2023 Jun;24(6):e270-e283. doi: 10.1016/S1470-2045(23)00157-2. Lancet Oncol. 2023. PMID: 37269858 Free article. Review.
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop.
Pe M, Voltz-Girolt C, Bell J, Bhatnagar V, Bogaerts J, Booth C, Burgos JG, Cappelleri JC, Coens C, Demolis P, Enzmann H, Giesinger JM, Gilbert A, Groenvold M, Kluetz P, Piccinin C, Postmus D, Quinten C, Ryll B, Sasseville M, Schlichting M, Schuerer H, Schiel A, Shaw JW, Smith AW, Tezuka S, Torre C, van der Graaf WTA, Wieseler B, Wittenbecher F, Reijneveld JC, Mol P. Pe M, et al. Lancet Oncol. 2025 Jun;26(6):687-690. doi: 10.1016/S1470-2045(25)00150-0. Epub 2025 Apr 14. Lancet Oncol. 2025. PMID: 40245904 No abstract available.
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials.
Gyawali B, Eisenhauer EA, van der Graaf W, Booth CM, Cherny NI, Goodman AM, Koven R, Pe ML, Marini BL, Mohyuddin GR, Pond GR, Sengar M, Soto-Perez-de-Celis E, Trapani D, Tregear M, Wilson BE, Tannock IF. Gyawali B, et al. Among authors: pe ml. Lancet Oncol. 2025 Feb;26(2):e80-e89. doi: 10.1016/S1470-2045(24)00451-0. Lancet Oncol. 2025. PMID: 39914429 Review.
Guidance for discussants of randomized cancer trials at major meetings.
Eisenhauer EA, Abdihamid O, Booth CM, Cherny N, Fojo AT, Gyawali B, Marini BL, Mohyuddin GR, Pe M, Pond GR, Soto-Perez-de-Celis E, Tannock IF, Trapani D, Tregear M, van der Graaf WTA, Wilson BE. Eisenhauer EA, et al. Among authors: pe m. Eur J Cancer. 2025 May 2;220:115357. doi: 10.1016/j.ejca.2025.115357. Epub 2025 Mar 7. Eur J Cancer. 2025. PMID: 40117861
Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs.
van der Weijst L, Machingura A, Alanya A, Lidington E, Velikova G, Flechtner HH, Schmidt H, Lehmann J, Ramage JK, Ringash J, Wac K, Oliver K, Taylor KJ, Wintner L, Senna LPC, Koller M, Husson O, Bultijnck R, Wilson R, Singer S, Bjelic-Radisic V, van der Graaf WTA, Pe M; EORTC Quality of Life Group. van der Weijst L, et al. Among authors: pe m. Eur J Cancer. 2024 Nov;212:114313. doi: 10.1016/j.ejca.2024.114313. Epub 2024 Sep 18. Eur J Cancer. 2024. PMID: 39305741 Free article.
Assessing Temporal Emotion Dynamics Using Networks.
Bringmann LF, Pe ML, Vissers N, Ceulemans E, Borsboom D, Vanpaemel W, Tuerlinckx F, Kuppens P. Bringmann LF, et al. Among authors: pe ml. Assessment. 2016 Aug;23(4):425-435. doi: 10.1177/1073191116645909. Assessment. 2016. PMID: 27141038
151 results